Natera (NTRA) on Monday announced a new policy for commercial coverage of its cell-free DNA fetal RhD noninvasive prenatal test in the US.
Under the new policy, coverage of fetal RhD testing will be available when a pregnancy may be facing risk for alloimmunization, when paternal antigen typing is unavailable or heterozygous, and if a patient declines amniocentesis or it is not recommended for the pregnancy, effective January, the company said.
Natera said fetal RhD noninvasive prenatal test is offered through its women's health suite of products and can be carried out as early as nine weeks gestation.
Price: 177.74, Change: +0.82, Percent Change: +0.46
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。